Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence AUSTIN, ...
Natera Inc. NTRA shares are up on Tuesday as the company announced promising results from a prospective study regarding its Signatera molecular residual disease (MRD) test. • Natera stock is showing ...
11 scientific abstracts, including 4 oral presentations and a concurrent publication in Nature Medicine, underscore how Signatera MRD can improve quality of life for patients with genitourinary ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage ...
Solidifies Natera’s Treatment on MRD (TOMR) approach as the new standard of care in MIBC, enabling precision interventions for MRD-positive patients while sparing MRD-negative patients from ...
13don MSN
Why is Natera stock gaining Tuesday?
Natera Inc. NTRA stock is up Tuesday as the company celebrates a significant milestone with the National Comprehensive Cancer ...
Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter can be downloaded here.
New findings show that Signatera status can help identify high-risk patients and inform non-operative management and surveillance strategies Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free ...
Prospective study published in Clinical Cancer Research shows that women >70 who tested Signatera MRD-negative could avoid surgery and remain progression-free While pET can be an alternative to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results